National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Jump to:
loading...
Preferred Name

Yttrium Y-90 Ibritumomab Tiuxetan
Synonyms

Y 90 Zevalin

yttrium Y90 ibritumomab tiuxetan

Yttrium Y 90 Ibritumomab Tiuxetan

Y 90 ibritumomab tiuxetan

Y 90 Ibritumomab Tiuxetan

Yttrium Y-90 Ibritumomab Tiuxetan

IDEC-Y2B8 monoclonal antibody

YTTRIUM Y-90 IBRITUMOMAB TIUXETAN

IDEC-Y2B8
Definitions

A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.
ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1812
Accepted_Therapeutic_Use_For

Non-Hodgkin's Lymphoma
ALT_DEFINITION

A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other types of B-cell tumors. It is made up of the monoclonal antibody ibritumomab plus the radioisotope yttrium Y 90. It binds to the protein called CD20, which is found on B cells. The radiation in the yttrium Y 90 may kill the cancer cells. Y 90 ibritumomab tiuxetan is a type of radiopharmaceutical.
code

C1812
Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537
Contributing_Source

CTRP

FDA

GDC
DEFINITION

A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.
Display_Name

Yttrium Y-90 Ibritumomab Tiuxetan
FDA_UNII_Code

QA846JAV5B
FULL_SYN

Y 90 Zevalin

yttrium Y90 ibritumomab tiuxetan

Yttrium Y 90 Ibritumomab Tiuxetan

Y 90 ibritumomab tiuxetan

Y 90 Ibritumomab Tiuxetan

Yttrium Y-90 Ibritumomab Tiuxetan

IDEC-Y2B8 monoclonal antibody

YTTRIUM Y-90 IBRITUMOMAB TIUXETAN

IDEC-Y2B8
Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C38896
Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909
label

Yttrium Y-90 Ibritumomab Tiuxetan
Legacy Concept Name

Y_90_Ibritumomab_Tiuxetan
Maps_To

Yttrium Y-90 Ibritumomab Tiuxetan
NCI_Drug_Dictionary_ID

38483
NSC Number

710085
PDQ_Closed_Trial_Search_ID

38483
PDQ_Open_Trial_Search_ID

38483
Preferred_Name

Yttrium Y-90 Ibritumomab Tiuxetan
prefixIRI

Thesaurus:C1812
Semantic_Type

Amino Acid, Peptide, or Protein

Pharmacologic Substance
UMLS_CUI

C0879283
subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129819

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1511
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display